These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Risk for hyperkalemia during long-term treatment with angiotensin-converting enzyme inhibitors in insulin-dependent type 2 diabetics in relation to the glomerular filtration rate]. Raml A, Schmekal B, Grafinger P, Biesenbach G. Dtsch Med Wochenschr; 2001 Nov 23; 126(47):1327-30. PubMed ID: 11719857 [Abstract] [Full Text] [Related]
26. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Weir MR, Rolfe M. Clin J Am Soc Nephrol; 2010 Mar 23; 5(3):531-48. PubMed ID: 20150448 [Abstract] [Full Text] [Related]
27. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania. Gluhovschi G, Mateş A, Gluhovschi C, Golea O, Gădălean F, Somai M, Ene I, Petrica L, Velciov S. Rom J Intern Med; 2014 Mar 23; 52(1):30-8. PubMed ID: 25000676 [Abstract] [Full Text] [Related]
36. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. N Engl J Med; 2004 Aug 05; 351(6):543-51. PubMed ID: 15295047 [Abstract] [Full Text] [Related]
40. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Am J Manag Care; 2015 Sep 05; 21(11 Suppl):S212-20. PubMed ID: 26619183 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]